AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 APR 19 - (NewsRx.com & NewsRx.net) -- The results of a four-year, multi-center study published in the April 5, 2001, issue of the American Journal of Medicine indicate that hormone replacement therapy did not reduce the incidence of fractures or height loss in postmenopausal, non-osteoporotic women.
The Heart Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo controlled, secondary prevention trial of cardiovascular disease, was designed to determine if estrogen plus progestin reduces the incidence of fractures or height loss in postmenopausal women with coronary disease. Twenty clinical centers in the U.S., including the University of Pittsburgh, the University of California (San Francisco and San Diego), and Wake Forest University, enrolled a total of 2,763 women.
Researchers randomly assigned 1,380 of the participants to the estrogen/progestin group. These women received 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate in one tablet daily. The remaining 1,383 received a placebo. Participants ranged in age from 44 to 79 years; approximately two-thirds were 65 years of age or older when the investigation began. Fewer than 15 % of the women had osteoporosis based on their bone ...
Source: HighBeam Research, Study Finds No Reduction of Fractures or Height Loss Associated With...